LECOM Health

Amyloid-Targeting Therapies

Dr. James Lin: A New Horizon in Alzheimer’s Care: Targeting the Disease Itself

Dr. James Lin: A New Horizon in Alzheimer’s Care: Targeting the Disease Itself

For countless families, an Alzheimer’s diagnosis has long felt like an irreversible sentence, a slow fading of memories, and a gradual loss of connection. The journey is marked by a search for ways to manage symptoms, but the underlying disease progression has remained a formidable challenge. Today, however, a new horizon is emerging in Alzheimer's care, offering not just management, but a direct intervention against the disease's core pathology. Innovative treatments known as amyloid-targeting therapies...Read More »

LECOM Health is First in the Region to Provide Amyloid-Targeting Therapies to Treat Alzheimer’s Disease

LECOM Health is First in the Region to Provide Amyloid-Targeting Therapies to Treat Alzheimer’s Disease

FDA-approved treatments administered as intravenous infusions Erie, Pa. (March 18, 2025) — LECOM Health is the first healthcare provider in the Erie region to offer amyloid-targeting therapies (ATT), which are monoclonal antibodies aimed at the amyloid-beta cascade for the treatment of early symptomatic Alzheimer’s Disease. FDA-approved medications being administered are Leqembi and Kisunla, which target the biomarkers related to AD and potentially slow the decline of the disease. Medication is administered as a 30-minute to...Read More »

Looking for assistance?

This is default text for notification bar